Background: One of the leading causes of death in the United States is hepatic fibrosis. For the treatment of liver disease, bone marrow mesenchymal stem cells have been advocated.fibrosis. Different types of fibrosis may be alleviated by simvastatin. organs.BM-MSCs and BM-MSCs were compared in the research. as well as simvastatin for the treatment of carbon-induced liver fibrosis tetrachloride. Methods: Fifty rats were divided into three groups: CCl4 was administered into rats in groups II and III to induce fibrous liver disease. CCL4 was injected into the rats in Group III. BM-MSCs are given intravenously in group IV, which consists of one dosage. CCL4 was injected into the rats, and they were subsequently administered simvastatin orally once daily for Eight months. Participants in Group V were administered BM-MSC as well as simvastatin. Blood samples were collected at the conclusion of the experiment. collected and liver tissues were processed for biochemical examination histological and immunohistochemical analysis CCL4 was the result. There was a large increase in liver enzymes and the destruction of normal hepatic structures, as well as a considerable rise in the mean area percentage of collagen fibre deposition and TGFexpression levels. There was an improvement in liver enzymes and histological structure, however the anti-fibrotic impact of BM-MSC was superior than the anti-fibrotic effect of simvastatin. The combination of BM- MSC and simvastatin had a more powerful anti-fibrotic impact and protected liver tissue's histological structure than simvastatin alone. Conclusion: The combination of BM-MSCs and simvastatin improves liver fibrosis produced by CCl4 therapy Liver fibrosis, CCL4, BM-MSCs, simvastatin, TGF- are some of the key terms